06.12.2005 23:39:00
|
Alcon Announces Wolfgang Reichenberger to Leave Board
Mr. Reichenberger has been a director of Alcon since its initialpublic offering in 2002 and has contributed greatly to Alcon'sstrategic business and financial direction over the past three years.Alcon extends its thanks and appreciation to Mr. Reichenberger for hiscontribution to the Company and wishes him every success in his futureendeavors.
About Alcon
Alcon, Inc. is the world's leading eye care company. Alcon, whichhas been dedicated to the ophthalmic industry for more than 50 years,develops, manufactures and markets pharmaceuticals, surgical equipmentand devices, contact lens care solutions and other vision careproducts that treat diseases, disorders and other conditions of theeye. Alcon's majority shareholder is Nestle, S.A., the world's largestfood company.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novartis AGmehr Nachrichten
28.02.25 |
Handel in Europa: STOXX 50 präsentiert sich letztendlich schwächer (finanzen.at) | |
28.02.25 |
Verluste in Europa: STOXX 50 am Freitagnachmittag mit Abgaben (finanzen.at) | |
28.02.25 |
Press Release: Novartis oral Fabhalta(R) -2- (Dow Jones) | |
28.02.25 |
Press Release: Novartis oral Fabhalta(R) (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G) (Dow Jones) | |
28.02.25 |
Handel in Europa: So steht der STOXX 50 am Mittag (finanzen.at) | |
28.02.25 |
Schwacher Wochentag in Europa: STOXX 50 beginnt Handel in der Verlustzone (finanzen.at) | |
27.02.25 |
Donnerstagshandel in Zürich: SLI zeigt sich zum Ende des Donnerstagshandels leichter (finanzen.at) | |
27.02.25 |
Verluste in Zürich: SMI präsentiert sich schlussendlich leichter (finanzen.at) |
Analysen zu Novartis AGmehr Analysen
25.02.25 | Novartis Neutral | JP Morgan Chase & Co. | |
20.02.25 | Novartis Outperform | Bernstein Research | |
18.02.25 | Novartis Buy | Deutsche Bank AG | |
13.02.25 | Novartis Neutral | UBS AG | |
12.02.25 | Novartis Buy | Deutsche Bank AG |
Aktien in diesem Artikel
Novartis AG | 80,10 | -0,27% |
|
Indizes in diesem Artikel
NYSE US 100 | 17 198,92 | -0,27% |